On July 27, 2017, PreciThera Inc., a privately-held, precision medicine company dedicated to the design and development of innovative biological therapeutics for the treatment of orphan bone diseases, announced the completion of a Series A Financing in an aggregate amount of $36 million. Investors participating in the financing included Sanderling Ventures, Arix Bioscience, Fonds de solidarité FTQ, CTI Life Sciences and Emerillon Capital.
PreciThera Inc. will use proceeds of the Series A financing to develop new molecules and to advance its lead candidate through IND and into clinical studies, aiming to achieve truly disease-modifying outcomes for patients, by leveraging both a novel understanding of the biology of these disorders and its precision medicine strategy.
Osler, Hoskin & Harcourt LLP represented PreciThera Inc. with a team led by Shahir Guindi, which included Sophie Amyot and Marjolaine Verdon-Akzam (Corporate Finance and Securities).